Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18854455 | 1.00 | SLC6A3 (0.32) | SLC6A3CXCR2 | |
| SCHEMBL17028217 | 1.00 | SLC6A3 (0.32) | SLC6A3CXCR2 | |
| SCHEMBL16168996 | 0.84 | HDAC4 (0.36) | CXCR2 | |
| SCHEMBL19594932 | 0.83 | SLC6A3 (0.33) | SLC6A3 | |
| SCHEMBL18862528 | 0.83 | SLC6A3 (0.33) | SLC6A3 | |
| SCHEMBL16341000 | 0.83 | SLC6A3 (0.33) | SLC6A3 | |
| SCHEMBL18854454 | 0.83 | SLC6A3 (0.33) | SLC6A3 | |
| SCHEMBL17041222 | 0.83 | SLC6A3 (0.33) | SLC6A3 | |
| SCHEMBL28917911 | 0.83 | SLC6A3 (0.33) | SLC6A3 | |
| SCHEMBL16340999 | 0.83 | SLC6A3 (0.33) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051310-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, BTK, NOX4 | SLC6A3 972/4885CXCR2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.